Publications

BibTex format

@article{Turner:2017:cid/ciw835,
author = {Turner, HC and Bettis, AA and Chu, BK and McFarland, DA and Hooper, PJ and Mante, SD and Fitzpatrick, C and Bradley, MH},
doi = {cid/ciw835},
journal = {Clinical Infectious Diseases},
pages = {728--735},
title = {Investment success in public health: an analysis of the cost-effectiveness and cost-benefit of the global programme to eliminate lymphatic filariasis},
url = {http://dx.doi.org/10.1093/cid/ciw835},
volume = {64},
year = {2017}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background.It has been estimated that $154 million per year will be required during 2015–2020 to continue the Global Programme to Eliminate Lymphatic Filariasis (GPELF). In light of this, it is important to understand the program’s current value. Here, we evaluate the cost-effectiveness and cost-benefit of the preventive chemotherapy that was provided under the GPELF between 2000 and 2014. In addition, we also investigate the potential cost-effectiveness of hydrocele surgery.Methods.Our economic evaluation of preventive chemotherapy was based on previously published health and economic impact estimates (between 2000 and 2014). The delivery costs of treatment were estimated using a model developed by the World Health Organization. We also developed a model to investigate the number of disability-adjusted life years (DALYs) averted by a hydrocelectomy and identified the cost threshold under which it would be considered cost-effective.Results.The projected cost-effectiveness and cost-benefit of preventive chemotherapy were very promising, and this was robust over a wide range of costs and assumptions. When the economic value of the donated drugs was not included, the GPELF would be classed as highly cost-effective. We projected that a typical hydrocelectomy would be classed as highly cost-effective if the surgery cost less than $66 and cost-effective if less than $398 (based on the World Bank’s cost-effectiveness thresholds for low income countries).Conclusions.Both the preventive chemotherapy and hydrocele surgeries provided under the GPELF are incredibly cost-effective and offer a very good investment in public health.
AU  - Turner,HC
AU  - Bettis,AA
AU  - Chu,BK
AU  - McFarland,DA
AU  - Hooper,PJ
AU  - Mante,SD
AU  - Fitzpatrick,C
AU  - Bradley,MH
DO  - cid/ciw835
EP  - 735
PY  - 2017///
SN  - 1058-4838
SP  - 728
TI  - Investment success in public health: an analysis of the cost-effectiveness and cost-benefit of the global programme to eliminate lymphatic filariasis
T2  - Clinical Infectious Diseases
UR  - http://dx.doi.org/10.1093/cid/ciw835
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000397304200005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://academic.oup.com/cid/article/64/6/728/2670371
UR  - http://hdl.handle.net/10044/1/76141
VL  - 64
ER  -

Download

DrHugoTurner

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)